Wednesday, July 27, 2016

BWI: Aimil Healthcare and Research Centre Organizes Medical Camps for Leucoderma Patients in Mumbai

 
Source : Aimil Pharmaceuticals Limited
Wednesday, July 27, 2016 6:44PM IST (1:14PM GMT)
 
Aimil Healthcare and Research Centre Organizes Medical Camps for Leucoderma Patients in Mumbai
 
Mumbai, Maharashtra, India

  • Camp benefits over 100 patients to win over Leucoderma
  • Aimil Healthcare and Research Centre to organize more camps across the country
  • To expand clinics in Punjab, Gujarat and Maharashtra
 
Aimil Healthcare and Research Centre organized one day camp for leucoderma patients at Hotel Orchid in Mumbai. The treatment recommended at the camp was based on the scientifically proven drug Lukoskin innovated by Defence Institute of Bio-Energy Research (DIBER), a unit of Defence Research and Development Organization (DRDO), Ministry of Defence, Govt. of India. The drug will help millions of people to fight against the highly prevalent social stigma of Leucoderma.
 

DRDO’s scientists took many years in developing the treatment regimen and establishing its efficacy and safety, making use of modern scientific techniques. The comprehensive Leucoderma treatment involves addressing the associated complications like incompatible food habits, nutritional deficiency, compromised immunity, Poor liver functions of the body and certain do’s and don’ts in food and life style to be followed for the utmost advantage of the patients and faster recovery.
 
Dr. Nitika Kohli, Aimil Healthcare and Research Centre, says, “We are using a unique combination of 5000 years old ancient research of Ayurveda and modern scientific technology. We at Aimil, want more and more patients to benefit and overcome from Leucoderma. It’s a myth that Leucoderma is a non-curable disease; however, with the development of Lukoskin, changes in dietary and lifestyle habits, we can fight Leucoderma. At Aimil, we don’t only provide medical consultation to the patients, we also provide counselling sessions to patients and their families who have different misconceptions about the disease and help them fight the social stigma and help them regain the confidence.
 
Since inception, Aimil Healthcare and Research Centre has treated over 50,000 patients across the country and abroad. With the help of DRDO’s product Lukoskin, about 31,500 patients, have recovered to their utmost satisfaction while the rest are in different phases of recovery, based on the marvelous healing properties of the selected rare herbs. More than 100 Leucoderma patients visited the camp in Mumbai and sought treatment for the disease. Aimil Healthcare and Research Centre is planning for more camps in different parts of the country. Aimil Healthcare and Research Centre aims to reach out to all those who are affected by Leucoderma and are organizing healthcare camps in order to assist the patients with the right guidance and consultation to fight Leucoderma.  In Mumbai, the next Leucoderma camp is scheduled for August 21, 2016.
 
Persistent to its commitment towards healthcare and reach more areas of the nation, Aimil Healthcare and Research Centre has planned its expansion in Punjab, Gujarat and Maharashtra and will be setting up clinics that will specialize in Leucoderma and diabetes. The clinics will provide recommended medicine for treating Leucoderma, Lukoskin, innovated by Defence Institute of Bio-Energy Research (DIBER), a unit of Defence Research and Development Organization (DRDO), Ministry of Defence, Govt. of India. BGR-34, country’s first anti-diabetic ayurvedic drug with DPP4 inhibitory Activity and designed for type 2 Diabetes will also be available at the clinics. Lukoskin and BGR-34 have been formulated with a combination of different fractions & quantity of best herbs listed in Ayurvedic ancient texts. 

Photo Caption: Lukoskin
 

 
Media Contact Details

Varsha Mahale, varsha@fuzionpr.co.in,

 

To ensure that you continue to receive email from Business Wire India in your inbox, please add businesswireindia.com to your Address Book or Safe List.

 
To submit a press release, click here.
To unsubscribe or modify your Business Wire India settings, please visit your profile page on Business Wire India.

Connect with us on: Facebook | Twitter | Google+
 
 

No comments:

Post a Comment